Jagsonpal Pharmaceuticals growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+6.9%	+6.7%
EBITDA	+13.7%	+19.4%
Net Income	−22.2%	+17.3%
EPS (adj.)	−22.2%	+17.3%
Total Assets	+13.8%	+17.5%
Total Equity	+15.1%	+20.2%
Free Cash Flow	−14.8%	+5.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JAGSNPHARM₹230.96

Jagsonpal Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersAMRUTANJAN NGLFINE SYNCOMF HESTERBIO SIGACHI LINCOLN WINDLASMcap ₹1,547 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+6.9	+6.7
EBITDA	+13.7	+19.4
Net Income	-22.2	+17.3
EPS (adj.)	-22.2	+17.3
Total Assets	+13.8	+17.5
Total Equity	+15.1	+20.2
Free Cash Flow	-14.8	+5.5

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.